Quince Therapeutics Seeks Strategic Alternatives After Lead Drug Failure, Shares Fall Sharply
Quince Therapeutics plunged nearly 40% in premarket trading after announcing its lead candidate failed to meet trial endpoints. With no other products in the pipeline and limited cash, the company has hired LifeSci Capital to explore strategic options, including a possible reverse merger, while warning of financing, listing and restructuring risks.